Allurion Technologies Appoints Four Board Members
Allurion Technologies announced the appointment of Michael Davin, Gail Zauder, Todd Zavodnick, and Krishna Gupta to its board of directors.
As Cynosure’s chairman, president, and chief executive officer from 2003 to 2017, Davin oversaw sales growth from $20 million to $430 million, including significant international expansion. He led the company’s initial public offering and listing on the NASDAQ and executed key acquisitions.
Zauder is the managing partner of Elixir Advisors, a financial and strategic advisory firm she founded in 2002. Prior to founding Elixir, Zauder was a managing director at Credit Suisse First Boston, where she was global head of the Luxury Goods Investment Banking Group.
Zavodnick is the chief commercial officer and president of aesthetics and therapeutics for Revance Therapeutics (NASDAQ:RVNC). He was president of International at Zeltiq Aesthetics prior to the company’s acquisition by Allergan plc in April 2017 for $2.5 billion. Earlier in his career, Zavodnick served in leadership roles at Galderma Laboratories, most recently as president and general manager, North America, generating $1.2 billion in division sales. Prior to that, he was president of Alcon China and Mongolia.
Gupta is the founder and managing partner of Romulus Capital, a venture capital firm that focuses on building, not betting on, science- and technology-enabled companies. Under Gupta’s leadership, Romulus has built a powerful portfolio of innovative companies and a global investor base from more than 20 countries.
“Our new board members have an extraordinary track record of successfully scaling medical device businesses and designing powerful consumer experiences,” said Samuel Levy, Allurion’s president and cofounder. “Just as importantly, they share our passion and determination to drive global adoption of our transformative weight loss technology.”